[go: up one dir, main page]

AR077416A2 - Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos - Google Patents

Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos

Info

Publication number
AR077416A2
AR077416A2 ARP100102577A ARP100102577A AR077416A2 AR 077416 A2 AR077416 A2 AR 077416A2 AR P100102577 A ARP100102577 A AR P100102577A AR P100102577 A ARP100102577 A AR P100102577A AR 077416 A2 AR077416 A2 AR 077416A2
Authority
AR
Argentina
Prior art keywords
flibanserine
preparation
same
stable polymorph
prepare medicines
Prior art date
Application number
ARP100102577A
Other languages
English (en)
Inventor
Enrica Dubini
Carlo Bombarda
Antoine Ezhaya
Heinrich Schneider
Original Assignee
Bidachem Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem Spa filed Critical Bidachem Spa
Publication of AR077416A2 publication Critical patent/AR077416A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicacion 1. El compuesto polimorfo A cristalino (forma A) de flibanserina 1, que tiene un máximo endotérmico a 161°C que se produce durante un análisis térmico usando DSC.
ARP100102577A 2001-08-02 2010-07-15 Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos AR077416A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19

Publications (1)

Publication Number Publication Date
AR077416A2 true AR077416A2 (es) 2011-08-24

Family

ID=26076670

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020102942A AR036208A1 (es) 2001-08-02 2002-08-02 Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos
ARP100102577A AR077416A2 (es) 2001-08-02 2010-07-15 Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP020102942A AR036208A1 (es) 2001-08-02 2002-08-02 Compuesto polimorfo estable de flibanserina, procedimiento industrial para su preparacion, y uso del mismo para preparar medicamentos

Country Status (26)

Country Link
EP (2) EP1518858A1 (es)
JP (1) JP3822601B2 (es)
KR (1) KR100899297B1 (es)
CN (1) CN1288147C (es)
AR (2) AR036208A1 (es)
AT (1) ATE288911T1 (es)
AU (1) AU2002331361B2 (es)
BR (1) BR0211601A (es)
CA (1) CA2450093C (es)
CO (1) CO5560572A2 (es)
DE (1) DE60202958T2 (es)
DK (1) DK1414816T3 (es)
EA (1) EA006400B1 (es)
ES (1) ES2237694T3 (es)
HR (1) HRP20040107B1 (es)
HU (1) HU228666B1 (es)
IL (2) IL159151A0 (es)
MX (1) MXPA04000913A (es)
MY (1) MY127294A (es)
NZ (1) NZ530510A (es)
PL (1) PL210224B1 (es)
PT (1) PT1414816E (es)
RS (1) RS50742B (es)
SI (1) SI1414816T1 (es)
UA (1) UA76767C2 (es)
WO (1) WO2003014079A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
CN102240289A (zh) * 2002-05-22 2011-11-16 贝林格尔英格海姆法玛两合公司 含氟班色林多晶型物a的药物组合物
JP2008540356A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬物乱用の治療方法
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
NZ573382A (en) * 2006-05-09 2012-02-24 Boehringer Ingelheim Int Use of flibanserin for the treatment of post-menopausal sexual desire disorders
ATE456369T1 (de) 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
AU2007286288A1 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
BRPI0716436B8 (pt) 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
US11492343B2 (en) 2016-01-31 2022-11-08 Xiaoming Meng Polymorph of flibanserin and preparation method thereof and use of same
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法
CN115919860B (zh) 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
DE60202958T2 (de) 2006-04-06
HU228666B1 (en) 2013-05-28
JP2004537597A (ja) 2004-12-16
BR0211601A (pt) 2004-08-24
CA2450093C (en) 2008-09-23
EA200400252A1 (ru) 2004-08-26
HUP0401201A3 (en) 2004-11-29
WO2003014079A8 (en) 2003-11-20
ES2237694T3 (es) 2005-08-01
MY127294A (en) 2006-11-30
AR036208A1 (es) 2004-08-18
PT1414816E (pt) 2005-04-29
SI1414816T1 (en) 2005-06-30
DK1414816T3 (da) 2005-04-11
EP1414816B1 (en) 2005-02-09
JP3822601B2 (ja) 2006-09-20
HRP20040107B1 (hr) 2012-02-29
CN1551879A (zh) 2004-12-01
PL364598A1 (en) 2004-12-13
DE60202958D1 (de) 2005-03-17
CA2450093A1 (en) 2003-02-20
EP1414816A1 (en) 2004-05-06
UA76767C2 (uk) 2006-09-15
HUP0401201A2 (hu) 2004-10-28
HRP20040107A2 (en) 2004-06-30
IL159151A (en) 2009-09-22
KR20040023704A (ko) 2004-03-18
EA006400B1 (ru) 2005-12-29
KR100899297B1 (ko) 2009-05-26
CO5560572A2 (es) 2005-09-30
IL159151A0 (en) 2004-06-01
NZ530510A (en) 2004-07-30
RS50742B (sr) 2010-08-31
AU2002331361B2 (en) 2008-06-05
HK1070063A1 (en) 2005-06-10
MXPA04000913A (es) 2004-10-27
EP1518858A1 (en) 2005-03-30
CN1288147C (zh) 2006-12-06
ATE288911T1 (de) 2005-02-15
YU7804A (sh) 2006-08-17
WO2003014079A1 (en) 2003-02-20
PL210224B1 (pl) 2011-12-30

Similar Documents

Publication Publication Date Title
AR077416A2 (es) Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos
SE0002102D0 (sv) Chemical compound
UY27740A1 (es) Nuevos compuestos
CO5231161A1 (es) 4-aminopicolinatos y su uso como herbicidas
AR040177A1 (es) Sal de formiato de o-desmetil-venlafaxina
PT1109812E (pt) Pirrolobenzodiazepinas
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
CO5310550A1 (es) Nuevo derivado de androstano antiinflamatorio, su polimorfo, sus formas cristalinas solvatadas, composiciones farmaceutias, proceso para prepararlo, intermediario
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
BR0108485A (pt) Derivados do antiviral azaindol
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
ATE403429T1 (de) Spiropyrazol-verbindungen
ES2187261B2 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
UY27852A1 (es) Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
DE60112960D1 (de) Kondensierte pyridoindolderivate
DE60121587D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
EA200201255A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
AR048235A1 (es) Un procedimiento para la sintesis de (7-metoxi-3,4-dihidro-1-naftalenil)acetonitrilo y su aplicacion en la sintesis de agomelatina
ECSP034532A (es) Derivados del 1-aminobutan-3-ol sustituido
IT1320107B1 (it) Procedimento per la preparazione di derivati tassanici.
AR057555A1 (es) Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
HN2001000021A (es) Nuevos derivados de amidas heterociclicas

Legal Events

Date Code Title Description
FB Suspension of granting procedure